ERBB2 and breast carcinoma: Luminal A-like accounts for 60–70% of breast cancer cases in the United States, followed by Luminal B-like HER2− at 10–20%, triple negative at 10–15%, and HER2-enriched and Luminal B-like HER2+ together at approximately 13–15% (Figure 1) [2,3].